The depth of tumor invasion beyond the outer border of the muscularis propria as a prognostic factor for T3 rectal/rectosigmoid cancer

Anticancer Research

Volumn 28, Issue 3 B, 2008, Pages 1773-1778

  Yoshida, Kiyohito ^a   Yoshimatsu, Kazuhiko ^a   Otani, Taisuke ^a   Yokomizo, Hajime ^a   Ogawa, Kenji ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

DBM; Prognostic factor; Rectal cancer; Rectosigmoid cancer

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LAMINA PROPRIA; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE; UNIVARIATE ANALYSIS;

AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 45949101994     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. WHO: The World Health Report. Geneva, World Health Organization, 1997.
2. Kapitejn E, Liefers GJ, Los LC, Kranenberg EK, Hermans J, Tollenaar RA, Moriya Y, van de Velde CJ and van Krieken JH: Mechanism of oncogenesis in colon versus rectal cancer. J Pathol 195: 171-178,2001.
3. Dukes CE: The classification of cancer of the rectum. J Pathol Bacteriol 35: 323-332, 1932.
4. Fenoglio-Preiser CM and Pascal RR: Other Tumours of the Large Intestine. Gastrointestinal and Oesophageal Pathology. In: Whitehead R (ed.). Edinburgh: Churchill Livingstone, pp. 747-768, 1989.
5. Willett CG, Badizadegan K, Ancukiewicz M and Shellito PC: Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 42: 167-173, 1999.
6. Steel MC, Woods R, Mackay JM and Chen F: Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. Aust NZ J Surg 72: 483-487, 2002.
7. Cawthorn SJ, Parums DV, Gibbs NM, A'Hern RP, Caffarey SM, Broughton CI and Marks CG: Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet 335: 1055-1059, 1990.
8. Greene FL (ed). AJCC Cancer Staging Manual, 6th ed. New York Springer-Verlag, 2002.
9. Miyoshi M, Ueno H, Hashiguchi Y, Mochizuki H and Talbot IC: Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients. Ann Surg 243: 492-498, 2006.
10. Hase K, Shatney C, Johnson D, Trollope M and Vierra M: Prognostic value of tumor 'budding' in patients with colorectal cancer. Dis Colon Rectum 36: 627-635, 1993.
11. Ueno H, Murphy J, Jass JR, Mochizuki H and Talbot IC: Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40: 127-132, 2002.
12. Tanaka M, Hashiguchi Y, Ueno H, Hase K and Mochizuki H: Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum 46: 1054-1059, 2003.
13. Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H and Talbot IC: A new prognostic staging system for rectal cancer. Ann Surg 240: 832-839, 2004.
14. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma First English Edition. Tokyo Kanehara & Co., Ltd., pp. 44-45, 1995.
15. Hase K, Mochizuki H, Utsunomiya K, Ueno H, Iwamoto K, Kuranaga K, Watanabe C and Tamakuma S: A study on Prognostic value of infiltrative growth (INF) in patients with colorectal cancer. Jpn J Coloproctol 49: 463-469, 1996 (in Japanese).
16. Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegard JN and Stenling R: Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br J Cancer 79: 577-581, 1999.
17. Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA: Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90: 675-684, 1998.
18. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K and Urosevic N: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85: 692-696, 2001.
19. Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, Wexner S, Givel JC and Belin B: Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 44: 364-372, 2001.
20. Buglioni S, D'Agnano I, Vasselli S, Perrone Donnorso R, D'Angelo C, Brenna A, Benevolo M, Cosimelli M, Zupi G and Mottolese M: p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. Am J Clin Pathol 116: 360-368, 2001.
21. Shibata D, Resale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, Jessup JM, Loda M and Summerhayes IC: The DCC protein and prognosis in colorectal cancer. N Engl J Med 335: 1727-1732, 1996.
22. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M and Gallinger S: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342: 69-77, 2000.
23. Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, Muretto P and Catalano G: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6: 2803-2807, 2000.
24. Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, van de Velde CJ, Verheijen JH, Lamers CB and Verspaget HW: Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 75: 1793-1801, 1997.
25. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994.
26. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117, 1996.
27. Graziano F and Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 14: 1026-1038, 2003.
28. Amato A, Scucchi L and Pescatori M: Tumor budding and recurrence of colorectal cancer. Dis Colon Rectum 37: 514-515, 1994.
29. Okuyama T, Oya M and Yamaguchi M: Budding (sprouting) as a useful prognostic marker in colorectal mucinous carcinoma. Jpn J Clin Oncol 32: 412-416, 2002.
30. Okuyama T, Oya M and Ishikawa H: Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol 83: 42-47, 2003.
31. Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H and Hase K: Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg 91: 327-333, 2004.
32. Merkel S, Wein A, Gunther K, Papadopoulos T, Hohenberger W and Hermanek P: High-risk groups of patients with stage II colon carcinoma. Cancer 92: 1435-1443, 2001.
33. Yoshimatsu K, Umehara A, Ishibashi K, Yokomizo H, Yoshida K, Fujimoto T, Watanabe K and Ogawa K: Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for Dukes' B colorectal cancer. Anticancer Res 26: 3089-3094, 2006.
34. Jass JR, Love SB and Northover JM: A new prognostic classification of rectal cancer. Lancet 1(8545): 1303-1306, 1987.
35. Jass JR, Ajioka Y, Allen JP, Chan YF, Cohen RJ, Nixon JM, Radojkovic M, Restall AP, Stables SR and Zwi LJ: Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 28: 543-548, 1996.
36. Cianchi F, Messerini L, Palomba A, Boddi V, Perigli G, Pucciani F, Bechi P and Cortesini C: Character of the invasive margin in colorectal cancer: does it improve prognostic information of Dukes staging? Dis Colon Rectum 40: 1170-1175, 1997.
37. Haslam AC, Pearson JM, Bisset DL, Michie HR and Hobbiss JH: A Dukes/Jass combination-is it more discriminating? Colorectal Dis 8: 418-422, 2006.
38. Mander BJ, Carney LJ, Scott HJ and Donaldson DR: Jass staging is a predictor of outcome following "curative" resection of Dukes' B colorectal carcinoma. Surgeon 4: 227-230, 2006.